


Amendments to the Claims

This listing of claims will replace all prior versions and listings of the claims in the application:


What is claimed is:

1. (Previously Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents a group of formula (A):



wherein R^{4a} represents C₁₋₆ alkyl, oxo, aryl, heteroaryl or heterocyclyl;


R^{5a} represents hydrogen, -C₁₋₆ alkyl, -C₁₋₆ alkylC₁₋₆ alkoxy, -C₁₋₆ alkoxycarbonyl, -C₃₋₈ cycloalkyl, -aryl, -heterocyclyl, heteroaryl, -C₁₋₆ alkyl-aryl, -CH(aryl)(aryl), -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-heteroaryl or -C₁₋₆ alkyl-heterocyclyl,

wherein R^{5a} may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₆ alkyl, polyhaloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, polyhaloC₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl or a group NR^{15a}R^{16a}, -CONR^{15a}R^{16a}, -NR^{15a}COR^{16a}, -NR^{15a}SO₂R^{16a} or -SO₂NR^{15a}R^{16a}, wherein R^{15a} and R^{16a} independently represent hydrogen, C₁₋₆ alkyl, aryl or together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl group;

m is 1;

p is 0, 1, 2 or 3, or when p represents 2, said R^{4a} groups may instead form a bridging group consisting of one or two methylene groups;

or R^1 represents a group of formula (F):



wherein t is 0, 1 or 2;

u is 1 or 2;

R^{4f} represents C_{1-6} alkyl or when t represents 2, said R^{4f} groups may instead form a bridging group consisting of one or two methylene groups;

R^{5f} represents $-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl C_{1-6} alkoxy, $-C_{3-8}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $-C_{1-6}$ alkyl-aryl, $-C_{1-6}$ alkyl- C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-heteroaryl, $-C_{1-6}$ alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl or -heterocyclyl-heterocyclyl;

wherein R^{5f} may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, halo C_{1-6} alkyl, polyhalo C_{1-6} alkyl, halo C_{1-6} alkoxy, polyhalo C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group $NR^{15f}R^{16f}$, $-CONR^{15f}R^{16f}$, $-NR^{15f}COR^{16f}$, $-NR^{15f}SO_2R^{16f}$ or $-SO_2NR^{15f}R^{16f}$, wherein R^{15f} and R^{16f} independently represent hydrogen or C_{1-6} alkyl or together form a heterocyclic ring;

Z^f represents CO or SO_2 ;

R^2 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2;

R^3 represents $-(CH_2)_q-NR^{11}R^{12}$


wherein q is 2, 3 or 4;

R^{11} and R^{12} together with the nitrogen atom to which they are attached represent piperidine optionally substituted by one or two R^{17} groups;


and R^{17} independently represents halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, OH, di C_{1-6} alkylamino or C_{1-6} alkoxy.

2. (Currently Amended) A compound according to claim 1 which is a compound selected from the group consisting of


E1




E2




E3




E4




E5




E6




E7




E8




E9




E10




E11




E12




E13




E14




E15




E16




E17




E18




E19




E20




E21




E22




E23




E24




E25




E26




E27




E28




E29




E30




E31




E32




E33




E34




E35




E36




E37




E38




E39




E40




E41




E42




E43




E44




E45




E46




E47




E48




E49




E54




E55




E56




E57




E58




E59




E60




E61




E62




E63




E64




E65




E66




E67




E68




E69




E70




E71




E72




E73




E81




E82




E83




E84




E85




E86




E87




E88




E89




E90




E91




E92




E93




E94




E95




E96




E97




E98




E99




E100




E101



E102




E103




E104

(1S,4S)-2-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2,5-diaza-bicyclo[2.2.1]heptane dihydrochloride


E105




E106




E107




E108




E109




E110




E111




E112




E113




E114




E115




E116




E117




E118




E119




E120




E121




E122



E123



E124



or and a pharmaceutically acceptable salt thereof.

3. (Previously Amended) A pharmaceutical composition which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4.-6. (Cancelled)

7. (Currently Amended) A method of treatment of cognitive impairment which comprises administering to a host human in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

8. (Cancelled).